Biography for Eric Palmer
Eric Palmer, Senior Editor
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at email@example.com.
Articles by Eric Palmer
Gilead Sciences' $84,000-per-treatment-course hep C drug Sovaldi reached blockbuster status twice over in the course of a single quarter. But instead of an aberration, a new report suggests it is a reflection of a trend that has been going on for 5 years and looks to be the new normal.
Actavis has been switching patients from the original version of the Alzheimer's treatment Namenda IR, which is going off patent, to its new once-a-day version. But the New York Attorney General was not impressed with its plan to just quit making the original version, and now Actavis has agreed to produce it for a couple more months to settle a lawsuit the AG filed this month.
The U.S. drugmaker will build a new campus in New Jersey for about 2,500 that it promises will pump up "collaboration, creativity and innovation," much as Biogen Idec, Novartis and others have done before it.
The FDA approved opioid painkiller Zohydro nearly a year ago as a med to provide relief for those with chronic pain. But the drug has been nothing but 11 months of aggravation for the agency and its leader, Commissioner Margaret Hamburg, who is now being called on to resign by organized anti-addiction groups who say the FDA has contributed to an epidemic of abuse in the country.
GlaxoSmithKline has been working with Belgian officials after "human error," resulted in 45 liters of cleaning liquid contaminated with poliovirus to get dumped into a city sewer system and subsequently into the Lasne River.
Price caps on "essential drugs" in India have been a sore point with domestic as well as Big Pharma players. The industry was further enraged when an Indian agency in May assumed the authority to add other products to the 350 already restricted. But the government of Prime Minister Narendra Modi is reining in the National Pharmaceutical Pricing Authority (NPPA), suggesting he may have a less populous approach to the industry than his predecessor.
Amgen is hoping to redeem its drug development rep by going to the FDA with an application for its new leukemia drug blinatumomab based on promising Phase II data, FierceBiotech reports.
Generic drugmaker Par Pharmaceutical is throwing in the towel in its long-running fight with Santarus ($SNTS) over its heartburn med Zegerid, and $100 million along with it. It reported today that the payment will settle their back-and-forth patent suit.
AstraZeneca's cost-cutting announcement actually had a hiring aspect to it. It is building a global network of IT centers that will replace the technology outsourcing it has been doing for more than a dozen years.
And so the M&A dance begins. Auxilium Pharmaceuticals today turned its back on a $2.2 billion buyout offer it received last week from Endo Pharmaceutical and said it would stick instead with its plan to merge with Canadian eye-drug maker QLT.